Company profile: GenoKey
1.1 - Company Overview
Company description
- Provider of AI-driven combinatorial analytics of genomic and clinical data via the PrecisionLife Innovation Engine to discover novel drug targets, identify drug repositioning candidates, and design diagnostic, prognostic and theranostic clinical decision support tools. Offers precision biopharma and healthcare solutions, including combinatorial risk scores to predict and prevent chronic diseases such as dementia, diabetes and cardiovascular diseases.
Products and services
- Combinatorial Risk Scores: Genomics-informed personalized risk models that predict and prevent chronic diseases by evaluating individual patient risks using combinatorial analysis of genetic and clinical data
- Clinical Decision Support: Theranostic-focused tools delivering diagnostic and prognostic insights to help select effective treatments for complex chronic diseases based on combinatorial patterns in genomic and clinical datasets
- Innovation Engine: AI-driven platform employing combinatorial analytics to discover novel drug targets, identify drug repositioning candidates, and architect diagnostic and clinical decision support tools for chronic diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to GenoKey
Ultima Genomics
HQ: United States
Website
- Description: Provider of a low-cost sequencing platform and related workflows, including the UG 100™ high-throughput system using a 200mm open silicon wafer with built-in automation; ppmSeq™ for rare event detection at one part per million for liquid biopsies and MRD; large-scale single-cell and spatial sequencing workflows; RNA-Seq for gene expression and isoform analysis; and genome-wide methylation sequencing compatible with standard tools.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ultima Genomics company profile →
Lexicon Pharmaceuticals
HQ: United States
Website
- Description: Provider of precise medicines for human disease, including INPEFA (sotagliflozin), a once-daily oral tablet that reduces the risk of cardiovascular death, heart failure hospitalization and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. Pipeline includes LX9211 for DPNP (AAK1) and sotagliflozin for type 1 diabetes (US regulatory) and HCM (preclinical).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lexicon Pharmaceuticals company profile →
Citation Growth
HQ: Canada
Website
- Description: Provider of cannabis cultivation, processing, and branding services, producing high-quality cannabis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Citation Growth company profile →
Tango Therapeutics
HQ: United States
Website
- Description: Provider of next-generation cancer therapies leveraging synthetic lethality, including TNG908 and TNG462, PRMT5 inhibitors for MTAP-deleted cancers; TNG260, a CoREST inhibitor aimed at reversing immune evasion in STK11-mutant cancers; and TNG348, a USP1 inhibitor for BRCA1/2-mutant and other HRD+ cancers, all in Phase 1/2 trials. Also provides a CRISPR-based functional genomics platform to identify synthetic lethal targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tango Therapeutics company profile →
Mammoth Biosciences
HQ: United States
Website
- Description: Provider of CRISPR-based diagnostics, therapeutics, and protein discovery solutions. The DETECTR Platform delivers instrument-free nucleic acid detection for disease; therapeutics offer precision genome editing using novel CRISPR-Cas enzymes; and a proprietary platform discovers new CRISPR systems and Cas proteins for applications in research, agriculture, and biodefense.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mammoth Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for GenoKey
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to GenoKey
2.2 - Growth funds investing in similar companies to GenoKey
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for GenoKey
4.2 - Public trading comparable groups for GenoKey
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →